Biovail Cardizem XL “approvable”
Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...
You may also be interested in...
Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.